H.C. Wainwright raised the firm’s price target on Praxis Precision (PRAX) to $1,245 from $340 and keeps a Buy rating on the shares. The firm says the company’s ulixacaltamide has been “transformative” while relutrigine is being overlooked and will drive “significant value” in the shares. H.C. Wainwright raised its peak sales estimates for both ulixacaltamide and relutrigine, with its relutrigine estimates now far ahead of the Street with peak sales expectations of $6.8B.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRAX:
- Praxis Precision price target raised to $554 from $353 at TD Cowen
- Praxis Precision price target raised to $1,200 from $450 at Piper Sandler
- Praxis Precision management to meet with Jefferies
- Praxis Precision Medicines: Clarified NDA Timelines and Catalyst‑Rich 2026 Underpin Reiterated Buy Rating
- Praxis Precision Medicines: Late-Stage CNS Pipeline and 2026 Catalyst Stack Underpin Reiterated Buy Rating